1. Effect of three angiotensin II antagonists, [Sar1, Thr8]-, [Sar1, Ile8]- and [Sar1, Ala8]angiotensin II on blood pressure and endocrine factors in normal subjects
T Hata, S Gotoh, K Masuo, S Saeki, M Nakamaru, Y Kumahara, T Ogihara, A Kumagai Eur J Clin Pharmacol . 1982;23(1):7-10. doi: 10.1007/BF01061369.
The biological effects of 1-Sarcosine, 8-Threonine angiotensin II ([Sar1, Thr8]ANG II) on blood pressure, plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were investigated in six normal subjects on an unrestricted diet, and compared with those of 1-Sarcosine, 8-Isoleucine ANG II ([Sar1, Ile8]ANG II) and 1-Sarcosine, 8-Alanine ANG II ([Sar1, Ala8]ANG II). All three ANG II analogues (AIIA) showed agonistic pressor activity, that of [Sar1, Ile8]ANG II being greater than that of [Sar1, Thr8]ANG II or [Sar1, Ala8]ANG II. The antagonistic effect of [Sar1, Thr8]ANG II on blood pressure was less than [Sar1, I1e8]ANG II or [Sar1, Ala8]ANG II. Both [Sar1, Ile8]ANG II and [Sar1, Ala8]ANG II increased PAC and blocked the steroidogenic action of ANG II, while [Sar1, Thr8]ANG II showed little effect on PAC. All three AIIA caused similar suppression of PRA and showed no inhibitory effect on the decrease in PRA produced by ANG II. These results indicate that [Sar1, Thr8]ANG II is an AIIA with weak agonistic pressor action and that it has vascular selective properties. It is also suggested that ANG II receptors in a variety of target organs are heterogeneous.
2. Localization of angiotensin II receptors in ovarian follicles and the identification of angiotensin II in rat ovaries
P De Silva, R C Speth, F M Bumpus, A Husain Proc Natl Acad Sci U S A . 1987 Apr;84(8):2489-93. doi: 10.1073/pnas.84.8.2489.
Specific, high-affinity (Kd approximately equal to 0.6 nM), and saturable (3.3 fmol/mg of tissue, wet weight) binding of 125I-labeled [Sar1,Ile8]angiotensin II to rat ovarian membranes was observed. Displacement of 125I-labeled [Sar1,Ile8]angiotensin II binding to rat ovarian membranes by angiotensin II analogs and fragments resembled the potency order of these compounds on angiotensin II receptors in other tissues: [Sar1,Ile8]angiotensin II greater than angiotensin II greater than des-Asp1-angiotensin II greater than angiotensin I greater than des-Asp1,Arg2-angiotensin II. Several unrelated peptides, including follicle-stimulating hormone at 10 microM, did not displace ovarian 125I-labeled [Sar1,Ile8]angiotensin II binding. Autoradiograms of 125I-labeled [Sar1,Ile8]angiotensin II binding to ovarian sections indicated that the angiotensin II receptor binding sites were localized exclusively to a subpopulation of follicles, occurring on the granulosa and theca interna cells. Other follicles were devoid of 125I-labeled [Sar1,Ile8]angiotensin II binding sites. Angiotensin II immunoreactive material was also identified in the ovary. The concentration of ovarian Ang II immunoreactivity was 8- to 75-fold greater than that of plasma, was not reduced in bilaterally nephrectomized rats, and was shown by high-pressure liquid chromatographic analysis to be the native angiotensin II octapeptide. The presence of angiotensin II and its receptor binding sites in the ovary suggests a role for angiotensin II as a regulator of ovarian function.
3. Localization of central angiotensin II receptors with [125I]-sar1, ile8-angiotensin II: periventricular sites of the anterior third ventricle
A R Maciejewski, M P Printz, D P Healy Neuroendocrinology . 1986;44(1):15-21. doi: 10.1159/000124615.
The radiolabeled angiotensin II (ANG II) antagonist, [N 125I]-sar1,ile8-ANG II, was used to study brain ANG II receptors by both homogenate binding and in vitro autoradiography. In homogenate preparations of the hypothalamus, thalamus, septum and midbrain (HTSM), [125I]-sar1,ile8-ANG II bound to a single class (Hill slope 0.84 +/- 0.05) of high affinity binding sites (KD 0.42 +/- 0.03 nM, Bmax 5.98 +/- fmol/mg protein). Competition for the [125I]-sar1,ile8-ANG II binding site in HTSM membranes demonstrated a rank order potency characteristic of binding to the ANG II receptor, with the unlabeled antagonist being slightly more potent than ANG II (Ki 0.22 +/- 0.03 vs 0.95 +/- 0.06 nM, respectively). Brain slices from the region of the rostral third ventricle were incubated with 0.5 nM[125I]-sar1,ile8-ANG II in the presence or absence of 1 microM ANG II and exposed to LKB Ultrofilm. Autoradiographic images of [125I]-sar1,ile8-ANG II binding revealed that structures situated within the anterior wall of the third ventricle, i.e. the lamina terminalis, were heavily labeled; including the subfornical organ, median preoptic nucleus and organum vasculosum laminae terminalis. These results show the utility of [125I]-sar1,ile8-ANG II as a probe to study brain ANG II receptors and provides pharmacological evidence for the rostral third ventricle as a possible site for central ANG II actions.
